电子处方笺市场－全球产业规模、份额、趋势、机会和预测：按组件、交付方式、最终用户、地区和竞争格局分析（2021-2031年）

全球电子处方笺市场预计将从 2025 年的 41.4 亿美元成长到 2031 年的 123.7 亿美元，复合年增长率达到 20.01%。

该市场的特点是医疗机构直接向处方笺数位化创建和传输处方。此流程旨在取代手写医嘱，最大限度地减少解读错误，并优化药品配发流程。推动此成长的关键因素包括：为提高病患安全，必须减少不利事件；以及政府法规强制要求采用数位化技术，以提高医疗互通性。这些驱动因素并非暂时的市场趋势，而是代表着向合规性和营运效率的根本结构转变。

然而，市场扩张仍面临许多障碍。确保资料安全稳健的复杂性以及实施所需的高昂基础设施成本是关键挑战，尤其是在发展中地区。患者隐私问题以及不联网系统之间的相容性不足也是重要的障碍。儘管存在这些挑战，但采用率指标表明，人们对这些平台的依赖程度很高。 Surescripts报告称，到2024年，其网路将处理26亿份电子处方笺，凸显了其庞大的使用规模。这项数据表明，儘管克服了安全全球部署的技术复杂性，该行业仍保持持续成长。

市场驱动因素

政府的利好政策以及相关法规和政策的实施是全球电子处方笺市场发展的关键驱动因素。世界各国政府正在推行数位医疗标准，以确保互通性，从而有效地以安全的电子系统取代纸本工作流程。这些法规不仅强制执行，还建立了广泛的医疗资料交换基础设施。例如，英国国家医疗服务体系（NHS）商业服务部门报告称，截至2025年10月，透过电子处方笺服务（EPS）配发的药品数量达到11.3亿份，占英格兰所有处方笺的97%。同样，Surescripts于2025年3月发布的《2024年影响报告》指出，该网络在2024年交换了272亿笔医疗资讯交易，充分展现了此类监管合作的巨大规模。

第二个关键驱动因素是迫切需要最大限度地减少用药错误并提高病人安全。手写处方笺潦草且容易被误解，而数位化处方则提供自动化的临床决策支持，例如药物交互作用检查和剂量提醒。这些功能可直接减少可预防的不利事件，而药物不良事件仍是导致患者伤害的主要原因之一。近期临床研究也支持这些安全优势。 Taylor & Francis 于 2024 年 12 月发表的一项研究发现，在一家三级医疗机构实施改进的电子处方笺后，整体处方笺错误率从 1.43% 降至 0.51%。这种保护患者健康的能力已得到证实，确保安全仍然是市场持续投资的关键驱动因素。

市场挑战

确保资料安全稳健的复杂性以及实施过程中高昂的基础设施成本，对全球电子处方笺市场的扩张构成了重大障碍。这些财务和技术难题为医疗服务提供者设定了很高的进入门槛，尤其对小规模诊所和医疗机构，特别是发展中地区的机构，造成了不成比例的影响。建构安全、可互通的网路所需的大量投资迫使各机构将大量资源从临床服务转移到网路安全基础设施。因此，高昂的拥有成本减缓了电子处方的普及，而持续存在的网路攻击威胁则削弱了相关人员从纸本工作流程全面过渡到数位系统所需的信任。

近期产业数据显示，医疗资讯系统存在许多漏洞，凸显了当前严峻的安全情势。美国医院协会 (AHA) 发布的《2025 年报告》预测，到 2024 年底，将有 2.59 亿美国人的受保护健康资讯遭到骇客攻击。这令人震惊的数据表明，电子处方笺平台必须应对的安全风险规模之大。应对如此广泛的漏洞需求推高了实施成本，增加了无缝全球解决方案推广的难度，并限制了市场的快速扩张能力。

市场趋势

电子预先核准(ePA) 工作流程自动化正在改变市场格局，它以即时演算法核准取代繁琐的人工流程。这一趋势直接消除了延误患者获得药物的行政瓶颈，并超越了简单的数位化，实现了完全「非接触式」审批。透过将支付方标准直接整合到处方工作流程中，医疗服务提供者可以即时获得批准结果，并显着减少电话和传真沟通所花费的时间。 Surescripts 在 2025 年 3 月发布的《2024 年影响报告》中重点强调了这一效率提升，指出非接触式预先核准功能将平均核准时间从一个多小时缩短至仅 34 秒，充分展现了先进自动化技术所能带来的显着效率提升。

同时，人工智慧 (AI) 在临床决策支援中的应用正在提高处方笺的准确性和速度。人工智慧演算法正被越来越多地用于自动化处理复杂任务，例如解读非结构化临床数据以及将说明指令转换为结构化程式码，从而最大限度地减少人为错误和人工输入的疲劳。这项技术进步使系统能够智慧地预测并自动填充处方笺详情，从而提高药房的资料完整性。正如 Hackensack Meridian Health 在 2025 年 7 月发布的新闻稿中所述，该公司与 DrFirst 合作，部署临床级人工智慧成功地自动映射了 30 万份药品样本中 86% 的患者适应症 (SIG)，这充分展现了人工智慧在简化大量处方操作方面的能力。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球电子处方笺市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按组件（解决方案{独立解决方案和整合解决方案}和服务）
  • 按交付类型（本地部署与基于 Web/云端的解决方案）
  • 依最终用户细分市场（医院、药局、诊所）进行分析
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美电子处方笺市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲电子处方笺市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区电子处方笺市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲电子处方笺市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美电子处方笺市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球电子处方笺市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Cerner Corporation
• Allscripts Healthcare Solutions, Inc.
• Epic Systems Corporation
• McKesson Corporation
• eClinicalWorks LLC
• GE Healthcare
• NextGen Healthcare, Inc.
• DrFirst, Inc.
• Greenway Health, LLC
• Practice Fusion, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global E-Prescription Market is projected to expand from USD 4.14 Billion in 2025 to USD 12.37 Billion by 2031, achieving a Compound Annual Growth Rate (CAGR) of 20.01%. This market is characterized by the digital creation and transmission of medical prescriptions from healthcare providers directly to pharmacies, a process designed to supersede handwritten orders to minimize interpretation errors and optimize medication dispensing workflows. The primary catalysts propelling this growth include the imperative need to lower adverse drug events for better patient safety and government mandates enforcing digital adoption to improve healthcare interoperability. These drivers represent fundamental structural changes toward regulatory compliance and operational efficiency rather than fleeting market trends.

However, market expansion faces significant obstacles, primarily the intricacy of guaranteeing robust data security and the substantial infrastructure costs required for implementation, especially in developing areas. Issues regarding patient privacy and the compatibility of disconnected systems persist as major barriers. Despite these challenges, adoption metrics demonstrate a heavy reliance on these platforms. As reported by Surescripts, 2.6 billion electronic prescriptions were processed through their network in 2024, highlighting the immense scale of utilization. This volume underscores the sector's continued momentum even as it navigates the technical complexities associated with secure global deployment.

Market Driver

The enforcement of favorable government mandates and regulatory policies acts as the primary catalyst for the global e-prescription market. Governments globally are implementing digital health standards to ensure interoperability, effectively replacing paper-based workflows with secure electronic systems. These regulations not only necessitate adoption but also establish a vast infrastructure for health data exchange. For instance, the NHS Business Services Authority reported in October 2025 that 1.13 billion items were dispensed via the Electronic Prescription Service (EPS), accounting for 97% of all prescription items in England. Similarly, Surescripts' '2024 Annual Impact Report' from March 2025 noted that their network exchanged 27.2 billion health intelligence transactions in 2024, demonstrating the massive scale facilitated by these regulatory connections.

A second critical driver is the urgent need to minimize medication errors and enhance patient safety. While manual prescribing methods are susceptible to illegibility and misinterpretation, digital alternatives provide automated clinical decision support, such as drug-drug interaction verifications and dosing alerts. These capabilities directly mitigate preventable adverse drug events, which remain a major source of patient harm. Recent clinical research validates these safety benefits; a study published by Taylor & Francis in December 2024 revealed that implementing e-prescribing modifications in a tertiary hospital lowered the overall prescribing error rate from 1.43% to 0.51%. This demonstrated capacity to safeguard patient health ensures that safety remains a primary incentive for continued market investment.

Market Challenge

The complexity of ensuring robust data security and the high infrastructure costs associated with implementation act as significant barriers to the expansion of the Global E-Prescription Market. These financial and technical hurdles create a steep barrier to entry for healthcare providers, disproportionately affecting smaller practices and institutions in developing regions. The substantial investment required to establish secure, interoperable networks forces organizations to divert critical resources from clinical services to cybersecurity infrastructure. Consequently, the high cost of ownership slows the adoption rate, while the persistent threat of cyberattacks erodes the trust necessary for stakeholders to fully transition from paper-based workflows to digital systems.

This precarious security landscape is emphasized by recent industry data highlighting the vulnerability of health information systems. According to the 'American Hospital Association' in 2025, the protected health information of 259 million Americans had been reported as hacked by the end of 2024. This alarming statistic illustrates the scale of the security risks that e-prescription platforms must mitigate. The necessity to defend against such widespread vulnerabilities drives up implementation costs and complicates the deployment of seamless global solutions, thereby restricting the market's potential for rapid scalability.

Market Trends

The automation of Electronic Prior Authorization (ePA) workflows is reshaping the market by replacing laborious manual processes with real-time, algorithmic approvals. This trend directly addresses the administrative bottlenecks that delay patient access to medication, advancing beyond simple digitization toward fully "touchless" adjudication. By integrating payer criteria directly into the prescribing workflow, providers can receive instant determinations, significantly reducing the time spent on phone calls and faxes. Surescripts highlighted this efficiency in their March 2025 '2024 Annual Impact Report,' noting that Touchless Prior Authorization capabilities lowered the average approval time from over an hour to merely 34 seconds, demonstrating the profound efficiency gains achievable through advanced automation.

Simultaneously, the integration of Artificial Intelligence for Clinical Decision Support is enhancing the accuracy and speed of prescription generation. AI algorithms are increasingly deployed to interpret unstructured clinical data and automate complex tasks such as translating narrative instructions into structured codes, thereby minimizing human error and manual entry fatigue. This technological evolution allows systems to intelligently predict and populate prescription details, ensuring higher data integrity for pharmacies. As evidenced in a July 2025 press release regarding Hackensack Meridian Health's partnership with DrFirst, the deployment of clinical-grade AI enabled the system to automatically map 86% of sigs (patient instructions) across a sample of 300,000 medications, validating the capability of AI to streamline high-volume prescribing operations.

Key Market Players

• Cerner Corporation
• Allscripts Healthcare Solutions, Inc.
• Epic Systems Corporation
• McKesson Corporation
• eClinicalWorks LLC
• GE Healthcare
• NextGen Healthcare, Inc.
• DrFirst, Inc.
• Greenway Health, LLC
• Practice Fusion, Inc.

Report Scope

In this report, the Global E-Prescription Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

E-Prescription Market, By Component

• Solutions {Standalone Solutions & Integrated Solutions}
• Services

E-Prescription Market, By Mode of Delivery

• On-Premises Solutions
• Web/Cloud-based Solutions

E-Prescription Market, By End-User Segment Analysis

• Hospitals
• Pharmacies & Clinics

E-Prescription Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global E-Prescription Market.

Available Customizations:

Global E-Prescription Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global E-Prescription Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Component (Solutions {Standalone Solutions & Integrated Solutions} & Services)
  • 5.2.2. By Mode Of Delivery (On-Premises Solutions & Web/Cloud-based Solutions)
  • 5.2.3. By End-User Segment Analysis (Hospitals, Pharmacies & Clinics)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America E-Prescription Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component
  • 6.2.2. By Mode Of Delivery
  • 6.2.3. By End-User Segment Analysis
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States E-Prescription Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Component
      • 6.3.1.2.2. By Mode Of Delivery
      • 6.3.1.2.3. By End-User Segment Analysis
  • 6.3.2. Canada E-Prescription Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Component
      • 6.3.2.2.2. By Mode Of Delivery
      • 6.3.2.2.3. By End-User Segment Analysis
  • 6.3.3. Mexico E-Prescription Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Component
      • 6.3.3.2.2. By Mode Of Delivery
      • 6.3.3.2.3. By End-User Segment Analysis

7. Europe E-Prescription Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Mode Of Delivery
  • 7.2.3. By End-User Segment Analysis
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany E-Prescription Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Mode Of Delivery
      • 7.3.1.2.3. By End-User Segment Analysis
  • 7.3.2. France E-Prescription Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Mode Of Delivery
      • 7.3.2.2.3. By End-User Segment Analysis
  • 7.3.3. United Kingdom E-Prescription Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Mode Of Delivery
      • 7.3.3.2.3. By End-User Segment Analysis
  • 7.3.4. Italy E-Prescription Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Component
      • 7.3.4.2.2. By Mode Of Delivery
      • 7.3.4.2.3. By End-User Segment Analysis
  • 7.3.5. Spain E-Prescription Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Component
      • 7.3.5.2.2. By Mode Of Delivery
      • 7.3.5.2.3. By End-User Segment Analysis

8. Asia Pacific E-Prescription Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Mode Of Delivery
  • 8.2.3. By End-User Segment Analysis
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China E-Prescription Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Mode Of Delivery
      • 8.3.1.2.3. By End-User Segment Analysis
  • 8.3.2. India E-Prescription Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Mode Of Delivery
      • 8.3.2.2.3. By End-User Segment Analysis
  • 8.3.3. Japan E-Prescription Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Mode Of Delivery
      • 8.3.3.2.3. By End-User Segment Analysis
  • 8.3.4. South Korea E-Prescription Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Mode Of Delivery
      • 8.3.4.2.3. By End-User Segment Analysis
  • 8.3.5. Australia E-Prescription Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Mode Of Delivery
      • 8.3.5.2.3. By End-User Segment Analysis

9. Middle East & Africa E-Prescription Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Mode Of Delivery
  • 9.2.3. By End-User Segment Analysis
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia E-Prescription Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Mode Of Delivery
      • 9.3.1.2.3. By End-User Segment Analysis
  • 9.3.2. UAE E-Prescription Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Mode Of Delivery
      • 9.3.2.2.3. By End-User Segment Analysis
  • 9.3.3. South Africa E-Prescription Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Mode Of Delivery
      • 9.3.3.2.3. By End-User Segment Analysis

10. South America E-Prescription Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Mode Of Delivery
  • 10.2.3. By End-User Segment Analysis
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil E-Prescription Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Mode Of Delivery
      • 10.3.1.2.3. By End-User Segment Analysis
  • 10.3.2. Colombia E-Prescription Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Mode Of Delivery
      • 10.3.2.2.3. By End-User Segment Analysis
  • 10.3.3. Argentina E-Prescription Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Mode Of Delivery
      • 10.3.3.2.3. By End-User Segment Analysis

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global E-Prescription Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Cerner Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Allscripts Healthcare Solutions, Inc.
• 15.3. Epic Systems Corporation
• 15.4. McKesson Corporation
• 15.5. eClinicalWorks LLC
• 15.6. GE Healthcare
• 15.7. NextGen Healthcare, Inc.
• 15.8. DrFirst, Inc.
• 15.9. Greenway Health, LLC
• 15.10. Practice Fusion, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer